T. Rowe Price Associates
PALI icon

T. Rowe Price Associates’s Palisade Bio PALI Stock Holding History

T. Rowe Price Associates’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$254K Buy
+121,152
New +$238K ﹤0.01% 2915
2026
Q1 		– Sell
-1,577,856
Closed -$3.71M – 3179
2025
Q4 		$3.71M Buy
+1,577,856
New +$3.03M ﹤0.01% 1498

Other funds holding PALI

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

T. Rowe Price Associates's PALI Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Palisade Bio (PALI) in Q2 2026: 121,152 shares worth $254K. The stake represents ﹤0.01% of the portfolio and ranks #2915 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in PALI as recently as Q4 2025.

T. Rowe Price Associates first reported a position in PALI in Q4 2025 and has held it in 2 quarters since. The position peaked at $3.71M in Q4 2025. 124 funds tracked by Wall St. Rank hold PALI as of Q2 2026.

  • T. Rowe Price Associates held 121,152 shares of Palisade Bio worth $254K as of Q2 2026.
  • Palisade Bio was a new T. Rowe Price Associates position in Q2 2026.
  • Palisade Bio made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2915 holding.
  • T. Rowe Price Associates first reported a position in Palisade Bio in Q4 2025 and has held it in 2 quarters since.
  • T. Rowe Price Associates's Palisade Bio position peaked at $3.71M in Q4 2025.
  • 124 funds tracked by Wall St. Rank held Palisade Bio as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.